항고혈압활성을 가진 고품질 국산 포도주를 개발하기 위하여 쉐리단 포도주 제조과정에서 다양한 약용식물과 머루 등을 첨가하여 이들이 쉐리단 포도주의 품질과 생리기능성에 미치는 영향을 조사하였다. 쉐리단 포도 주스에 머루를 첨가하여 발효시킨 쉐리단-머루 포도주가 에탄올 함량과 기호도가 가장 높았고 68.5%의 높은 항고혈압성 안지오텐신 전환효소(ACE) 저해활성을 보였다. 쉐리단-머루 포도주는 60일간 후발효 시켰을 때 ACE 저해활성은 80.7%(IC50: 28 mg/mL)로 상승하였고 기호성도 좋았다. 또한 60일 후발효 시킨 쉐리단-머루 포도주의 C18 solid phase 추출물은 본태성 고혈압쥐 (SHR)에서 항고혈압성이 확인되었다.

The goal of this study was to develop a high value Korean red wine possessing antihypertension activity. The effects of some medicinal plants and grapes on the alcohol fermentation process and the angiotensin I-converting enzyme (ACE) inhibitory activity of Vitis hybrid red wine were investigated. Various Vitis hybrid red wines were vinified by the fermentation of a mixture of Vitis hybrid must and some medicinal plants and grapes at 25oC for 10 days. Of these red wines, the Vitis hybrid-Vitis coignetiae red wine exhibited a high ethanol content of 12.0% and had a good level of acceptability. It also showed a high antihypertensive ACE inhibitory activity of 68.5%. After post-fermentation of 60 days, the ACE inhibitory activities of the Vitis hybrid-Vitis coignetiae red wine exhibited the highest ACE inhibitory activity of 80.7% (IC50: 28 mg/mL) and also had the best acceptability. The C18 solid phase extracts of the Vitis hybrid-Vitis coignetiae red wine, after 60 days post-fermentation, showed clear antihypertensive effects on spontaneously hypertensive rats. Our results reveal that the Vitis hybrid-Vitis coignetiae red wine has the potential to become a new functional red wine due to its good acceptability and high antihypertensive activity.